Dec 6, 2017

Randomized Placebo-Controlled Study Provides Encouraging Results for a Higher Dose Formulation of Vaxchora® (CVD 103-HgR) as a Potential Tool in Containing Cholera Epidemics

REDWOOD CITY, CA – December 6, 2017 - PaxVax announced findings from a study published in the December 2017 issue of Clinical and Vaccine Immunology that shows the utility of a single high-dose CVD 103-HgR live oral cholera vaccine in...


Jun 22, 2017

PaxVax and TerahVax Enter into Marketing and Distribution Agreement for Vaccine Availability in South Korea

REDWOOD CITY, CA – June 22, 2017 – PaxVax, Inc., a fully integrated specialty vaccine company focused on travel, and TerahVax, a vaccine specialized company launching vaccine products in Asia, announced today that they have entered into a marketing and...


Jun 8, 2017

CDC Recommends that Adults Traveling to Cholera-Affected Destinations Get Vaccinated with Vaxchora™ (Cholera Vaccine, Live, Oral)

REDWOOD CITY, CA – May 11, 2017 – PaxVax announced today that the U.S. Centers for Disease Control and Prevention (CDC) has adopted and published the recommendation of the Advisory Committee on Immunization Practice (ACIP) regarding the use of Vaxchora™...


May 8, 2017

PaxVax Initiates Clinical Trials of a Modernized Adenovirus Vaccine in Collaboration with the U.S. Army Medical Materiel Development Activity and the Walter Reed Army Institute of Research to Protect U.S. Military Personnel

Provides overhaul to more than 30-year-old Adenovirus Serotypes 4 and 7 vaccine against leading causes of Acute Respiratory Distress (ARD), which frequently results in severe pneumonia and hospitalization[1] REDWOOD CITY, CA – May 8, 2017 – PaxVax, a leading independent...


Jan 5, 2017

PaxVax Partners with National Institutes of Health and Department of Defense to Develop a New Virus-Like Particle Vaccine to Fight the Spread of Chikungunya

REDWOOD CITY, CA – January 5, 2017 – PaxVax announced today its partnership with the National Institutes of Health (NIH) and United States Department of Defense (DoD) on its chikungunya vaccine program. According to the terms of the collaboration, PaxVax...


Oct 24, 2016

PaxVax’s Vaxchora™ Now Available as the Only U.S. Approved Vaccine for Protection Against Cholera

REDWOOD CITY, CA – October 24, 2016 – PaxVax, Inc. announced that Vaxchora™ is now available in the United States (U.S.) as the country’s only vaccine for protection against cholera, a highly contagious intestinal diarrheal infection that can cause death...


Oct 11, 2016

PaxVax to Receive California Life Sciences Association’s 2016 Rising Star Award

REDWOOD CITY, CA – October 11, 2016 – PaxVax, Inc., a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases, today announced that it has been selected to receive the 2016 DiNA™ Rising Star...


Sep 21, 2016

PaxVax CEO Nima Farzan Joins Board of the Coalition for Epidemic Preparedness Innovations

REDWOOD CITY, CA – September 21, 2016 – PaxVax today announced its President and CEO, Nima Farzan, has been invited to join the interim board of the Coalition for Epidemic Preparedness Innovations (CEPI) as the Biotechnology Innovation Organization (BIO) delegate....


Sep 6, 2016

Specialty Vaccine Company PaxVax Appoints Philip K. Moody As Chief Financial Officer

REDWOOD CITY, CA – September 6, 2016 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Philip K. Moody as Chief Financial Officer (CFO) effective August 29, 2016. In this role, Mr....


Aug 29, 2016

PaxVax Inks Swiss Marketing and Distribution Agreement with Seqirus for Influenza Vaccines

REDWOOD CITY, California, USA – August 29, 2016 – PaxVax, a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases, today announced that the company has entered into a marketing and distribution agreement with...


Jun 23, 2016

CDC Advisory Committee On Immunization Practices Votes To Recommend Vaxchora, PaxVax’s Single-Dose Oral Cholera Vaccine

Vaxchora™ is the only licensed vaccine in the U.S. for protection against cholera REDWOOD CITY, CA – June 23, 2016 – PaxVax today announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted...


Jun 10, 2016

FDA Approves Vaxchora, PaxVax’s Single-Dose Oral Cholera Vaccine

Vaxchora™ is the only approved vaccine in the U.S. for protection against cholera PaxVax, today announced that it has received marketing approval from the United States (U.S.) Food and Drug Administration (FDA) for Vaxchora, a single-dose oral, live attenuated cholera...


Mar 30, 2016

PaxVax Named Best Early-Stage Company at Vaccine Industry Excellence (ViE) Awards

Washington, D.C. and Redwood City, Calif. – March 30, 2016 – PaxVax Inc., a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases, today announced that it was named Best Early-Stage Vaccine Biotech company...


Jan 8, 2016

PaxVax to Present at 33rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif. – January 8, 2015 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that Chief Executive Officer Kenneth Kelley will present at the annual J.P. Morgan Healthcare Conference in San Francisco on...


Dec 16, 2015

U.S. Food and Drug Administration Accepts Biologics License Application for PaxVax’s Single-Dose Oral Cholera Vaccine Vaxchora

Vaxchora™ also granted priority review status by FDA as a vaccine candidate addressing a tropical disease REDWOOD CITY, Calif. – December 16, 2015 – PaxVax Inc., a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against...


1 of 3123